Treatment of intraperitoneal implanted human ovarian carcinoma of nude mice by angiostatin gene and chemotherapy in vivo.
- Author:
Ping SUN
1
;
Bei-Hua KONG
Author Information
- Publication Type:Journal Article
- MeSH: Angiostatins; biosynthesis; genetics; Animals; Antineoplastic Agents; therapeutic use; Cisplatin; therapeutic use; Combined Modality Therapy; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; blood supply; pathology; therapy; Peritoneum; Random Allocation; Transplantation, Heterologous
- From: Acta Academiae Medicinae Sinicae 2008;30(1):91-94
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effects of angiostatin gene combined with chemotherapy on implanted human ovarian carcinoma of nude mouse.
METHODSThe mice were randomly divided into four groups after 7 days of the intraperitoneal injection of tumor cells (4 x 10(6)), and injected respectively with empty plasmid pcDNA3.0, angiostatin plasmid, cisplatin, and angiostatin plasmid + cisplatin. For combinational treatment, reagents were delivered in a timed fashion, where angiostatin plasmid was injected first, followed by cisplatin 24h later. The tumor samples were prepared to be used in the examinations of the expression of angiostatin with immunohistochemistry, of MVD in the tumor with immunohistochemistry, and of cell apoptosis with TUNEL staining.
RESULTSTumor growth and ascites formation were inhibited in all 3 groups except for the control group. The therapeutic effectiveness in the combined group was more significant than in the other two groups. In this group, MVD (32.5 +/- 4.3) was the lowest and apoptosis index (5.12 +/- 0.63) was the highest (P < 0.01).
CONCLUSIONSAngiostatin gene therapy combined with chemotherapy has a synergistic effect on the inhibition of ovarian cancer angiogenesis and ascites formation. Combining multiple therapies to treat ovarian cancer is an effective strategy.
